• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Products
    • Products
      • Our Products & Technologies
      • hRPCs for Retinal Disease
      • CTX cells for Stroke Disability
      • ReNcell Products
      • Publications
    • Clinical Trials
      • Clinical Trials
      • Phase 1/2a clinical trial in retinitis pigmentosa
      • Phase 2b Clinical trial in stroke disability (PISCES III)
      • Phase 2a clinical trial in stroke disability (PISCES-II)
      • Phase 1 clinical trial in stroke disability (PISCES)
      • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Products
    • Products
      • Our Products & Technologies
      • hRPCs for Retinal Disease
      • CTX cells for Stroke Disability
      • ReNcell Products
      • Publications
    • Clinical Trials
      • Clinical Trials
      • Phase 1/2a clinical trial in retinitis pigmentosa
      • Phase 2b Clinical trial in stroke disability (PISCES III)
      • Phase 2a clinical trial in stroke disability (PISCES-II)
      • Phase 1 clinical trial in stroke disability (PISCES)
      • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

News: Observational study in stroke

CEO presents at the 2015 Stem Cell meeting on the MESA

Section: News

  • News Centre
  • News
    • News Archive
  • Events
  • Media Coverage

Filter by:

  • Corporate
  • Product
    • Induced pluripotent stem cell (iPSC) Platform
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinitis Pigmentosa
    • CTX-derived Exosomes
  • Trial
    • Phase III clinical trial in stroke disability (PISCES-III)
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase II clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/II clinical trial in retinitis pigmentosa

© ReNeuron Group plc 2022 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer